Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

• Auteurs principaux: Elena M. Tosca (Auteur), Glenn Gauderat (Auteur), Sylvain Fouliard (Auteur), Mike Burbridge (Auteur), Marylore Chenel (Auteur), Paolo Magni (Auteur)
• Format: Livre
• Publié: Wiley, 2021-11-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non‐small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitor...